文献速递甲状腺疾病

良性甲状腺结节热消融再治疗临床结局:意大利甲状腺微创治疗组多中心研究

Clinical Outcomes of Thermal Ablation Re-Treatment of Benign Thyroid Nodules: A Multicenter Study from the Italian Minimally Invasive Treatments of the Thyroid Group.
PubMed 文献 · Thyroid · 2024-02-01

多中心回顾性队列纳入135例首次热消融后体积缩小<50%的良性甲状腺结节患者,再治疗后6和12个月体积缩小率分别为50%和52.2%;<30 mL结节再治疗体积缩小率优于首次治疗,>30 mL无差异。再治疗技术无效率51.9%、再生率12.6%、进一步治疗率15.6%;射频消融对技术无效和进一步治疗有保护作用,大结节(>30 mL)增加再治疗风险。

要点

  • 再治疗后6和12个月体积缩小率分别为50%和52.2%。
  • 再治疗技术无效率51.9%,再生率12.6%,进一步治疗率15.6%。
  • 射频消融对技术无效和进一步治疗有保护作用,大结节(>30 mL)增加再治疗风险。

核心结论

  • 这是首项评估首次热消融后体积缩小率<50%的症状性良性甲状腺结节再治疗结局的研究,小和中型结节(<30 mL)及射频消融后效果最佳,需前瞻性验证研究。

研究设计与样本

  • 多中心回顾性队列研究,纳入135例因良性甲状腺结节首次热消融后体积缩小<50%而接受热消融再治疗的患者。

主要发现

  • 再治疗后6和12个月体积缩小率分别为50%和52.2%。
  • 再治疗体积缩小率在小和中型结节(<30 mL)大于首次治疗,大结节(>30 mL)无差异。
  • 再治疗后技术无效率51.9%,再生率12.6%,进一步治疗率15.6%。
  • 射频消融对技术无效有保护作用(HR=0.40 [CI 0.24-0.65]),对需进一步治疗有保护作用(HR=0.30 [CI 0.12-0.76])。
  • 大结节体积(>30 mL)与再治疗风险增加相关(HR=4.52 [CI 1.38-14.82])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需前瞻性验证研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Thermal ablation (TA) is an established therapeutic option alternative to surgery in patients with solid benign thyroid nodules causing local symptoms. However, a variable part of thyroid nodules remain viable after these nonsurgical treatments, and as many as 15% of nodules treated with TA may require a second treatment over time. This study aimed to evaluate the outcomes of TA re-treatment on symptomatic benign thyroid nodules where the volume decreased by <50% after the first procedure ( = technique inefficacy). Methods: We performed a multicenter retrospective cohort study including patients who underwent re-treatment with TA for benign thyroid nodules, whose volume decreased by <50% after initial treatment. The primary aim was to evaluate volume and volume reduction ratio (VRR) over time and compare the 6- and 12-month VRR after first versus second treatment. The secondary aim was to identify protective or risk factors for technique inefficacy, regrowth, and further treatments, expressed as adjusted hazard ratios (HRs) and confidence interval [CI], after adjustment for sex, age, nodule volume, structure and function, nodule regrowth or symptom relapse, technique used and if the same technique was used for the first and second TA and time between them. Results: We included 135 patients. Re-treatment led to VRR of 50% and 52.2% after 6 and 12 months. VRR after re-treatment was greater than after first treatment in small and medium size nodules (<30 mL), while there were no differences for large nodules (>30 mL). After re-treatment technique inefficacy rate was 51.9%, regrowth rate was 12.6%, and further treatment rate was 15.6%. Radiofrequency ablation (RFA) was protective toward technique inefficacy (HR = 0.40 [CI 0.24-0.65]) and need of further treatments (HR = 0.30 [CI 0.12-0.76]). Large nodule volume (>30 mL) was associated with increased risk of re-treatment (HR = 4.52 [CI 1.38-14.82]). Conclusions: This is the first study evaluating the outcomes of re-treatment on symptomatic benign thyroid nodules with a VRR <50% after the initial TA treatment. Best results were seen in small and medium nodules (<30 mL) and after RFA. Prospective confirmatory studies are needed.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Bernardi S, Rosolen V, Barbone F, et al. Clinical Outcomes of Thermal Ablation Re-Treatment of Benign Thyroid Nodules: A Multicenter Study from the Italian Minimally Invasive Treatments of the Thyroid Group. Thyroid. 2024. PMID: 38149599. doi:10.1089/thy.2023.0501

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。